New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
09:21 EDTJAZZJazz Pharmaceuticals thesis remains intact, says Cowen
Cowen said the thesis for Jazz Pharmaceuticals remains intact after the company posted solid Q2 results. The firm cited strong sales, in-line spending, and increased revenue guidance and would be buyers of the stock at what they call "very protected" levels. Cowen has a $190 price target on Jazz.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:28 EDTJAZZJazz Pharmaceuticals price target raised to $220 from $201 at Leerink
Subscribe for More Information
July 29, 2015
15:52 EDTJAZZUSPTO review of Jazz patents negative but not unexpected, says BMO Capital
Subscribe for More Information
15:46 EDTJAZZJazz Pharmaceuticals says USPTO moving forward with review of Xyrem patents
Subscribe for More Information
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use